Lariosa-Willingham, Karen
Leonoudakis, Dmitri
Simon, Florian
Walker, Kendall
Guillaume, Philippe
Warren, Liling
Stratton, Jennifer
Funding for this research was provided by:
Teva Pharmaceutical Industries
Article History
Received: 26 May 2023
Accepted: 16 November 2023
First Online: 25 November 2023
Declarations
:
: All experimental protocols were approved by the Internal Animal Care and Use Committee (IACUC, Porsolt code n°F53 1031). The study was conducted according to the guidelines of the Declaration of Helsinki, in strict accordance with Council Directive No. 2010/63/UE of September 22, 2010 on the protection of animals used for scientific purposes, the French Decree No. 2013–118 of February 1, 2013 on the protection of animals for use and care of laboratory animals, and the recommendations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC agreement 001463 obtained in 2012 and renewed in June 2021).
: Not applicable.
: Teva Pharmaceuticals Industries Ltd. develops, produces and markets affordable, high quality generic drugs and specialty pharmaceuticals. Porsolt SAS is a contract research organization that conducted part of the study through a fee-for-service agreement with Teva Pharmaceuticals Industries Ltd. At the time of the study, PG, FS, KW were employed by Porsolt. KLW, DL, LW and JS were employed by Teva Pharmaceuticals Industries Ltd.